Population Health Research Institute
Acute Coronary Syndromes

ASPIRE (Completed)
Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation

< back

This pilot trial evaluated the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting and showed that  fondaparinux was comparable to UFH for clinical safety and efficacy outcomes. These data contributed to further evaluation of fondaparinux in arterial thrombosis.

Study Design: Pilot phase II, randomized, multicenter, blinded trial.

Intervention: Fondparinux vs. UFH. 

Length of Study: 6 months.

# of Patients: 350.

Patient Populations: Patients undergoing urgent or elective PCI for ACS or stable angina.


Presentations

Not available at this time.


Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S; ASPIRE Investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005;111(11):1390-7.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca